Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression
Overall survival longer than for chemotherapy in metastatic NSCLC with high PD-L1 expression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.